Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network

Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network

BackgroundWaldenström macroglobulinemia (WM) is a rare and indolent B-cell lymphoproliferative disorder with greater incidence in elderly patients where a precise algorithm of initial therapy is still not clear. Immunochemotherapy regimen consisting of dexamethasone, rituximab, and oral cyclophospha...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Vittorio Del Fabro, Uros Markovic, Sara Frazzetto, Roberta Sciortino, Claudia Bellofiore, Mary Ann Di Giorgio, Valerio Leotta, Anna Bulla, Angelo Curto Pelle, Federica Elia, Donato Mannina, Ugo Consoli, Giuseppe Mineo, Cesarina Giallongo, Alessandra Romano, Francesco Di Raimondo, Concetta Conticello
التنسيق: مقال
اللغة:English
منشور في: Frontiers Media S.A. 2024-06-01
سلاسل:Frontiers in Hematology
الموضوعات:
Waldenström macroglobulinemia
first line treatment
DRC regimen
four-week cycle
safety
الوصول للمادة أونلاين:https://www.frontiersin.org/articles/10.3389/frhem.2024.1425677/full

الانترنت

https://www.frontiersin.org/articles/10.3389/frhem.2024.1425677/full

مواد مشابهة